Pharmaceuticals
Lilly's Q2 FY2026 results were driven by incretin demand, with Mounjaro and Zepbound fueling revenue growth, while heavy investment in acquisitions and pipeline expansion weighed on profitability.
Key risk: High Leverage and Debt Burden
Long-term debt increased to $47.9 billion, a 40% rise year-over-year, leading to a debt-to-equity ratio of 1.41. High leverage may constrain financial flexibility and increase interest costs.
Other Pharmaceuticals companies